Literature DB >> 30595376

Bone mineral density correlates with survival after resection of extrahepatic biliary malignancies.

Siyuan Yao1, Toshimi Kaido2, Shinya Okumura1, Sena Iwamura1, Yosuke Miyachi1, Hisaya Shirai1, Atsushi Kobayashi1, Yuhei Hamaguchi1, Naoko Kamo1, Ryuji Uozumi3, Shintaro Yagi1, Shinji Uemoto1.   

Abstract

BACKGROUND & AIMS: Osteopenia is a condition in which bone mineral density (BMD) is lower than normal, and it is an important determinant of bone fragility. However, the utility of osteopenia in assessing the risks of surgery is unclear. This study investigated the impact of preoperative low BMD on the outcomes in patients undergoing resection of extrahepatic biliary cancers.
METHODS: A retrospective analysis was performed with 181 patients who underwent resections of extrahepatic biliary cancers between 2005 and 2015. Their BMD was measured on preoperative computed tomography images. Overall survival (OS) and recurrence-free survival (RFS) rates were compared according to BMD (normal vs. low), and the prognostic factors after surgery were assessed. Propensity score matching was used to minimize the bias in patient background.
RESULTS: Older age and female were strongly associated with low BMD. These factors were used to construct the propensity score model, which yielded a matched cohort of 52 legs in each group. The OS (21.2% vs. 53.9% at 5 years, p < .001) and RFS (21.8% vs. 64.6% at 5 years, p < .001) rates were significantly lower in patients with low BMD (osteopenia) than in those with normal BMD (non-osteopenia). Multivariable analyses showed that low BMD was an independent factor predictive of poor OS (hazard ratio [HR]: 2.343, 95% confidence interval [CI]: 1.362-4.129, p = .002) and poor RFS (HR: 3.648, 95% CI: 1.986-6.990, p=<.001).
CONCLUSIONS: Preoperative low BMD is closely related to mortality and cancer recurrence after the resection of extrahepatic biliary cancers. BMD screening in patients with cancer should be further highlighted in the oncology field.
Copyright © 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Biliary cancer; Bone mineral density; Osteopenia; Recurrence; Sarcopenia; Survival

Year:  2018        PMID: 30595376     DOI: 10.1016/j.clnu.2018.12.004

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  5 in total

1.  Preoperative Osteopenia Is Associated with Significantly Shorter Survival in Patients with Perihilar Cholangiocarcinoma.

Authors:  Jun Watanabe; Atsushi Miki; Yasunaru Sakuma; Kentaro Shimodaira; Yuichi Aoki; Yoshiyuki Meguro; Kazue Morishima; Kazuhiro Endo; Hideki Sasanuma; Alan Kawarai Lefor; Takumi Teratani; Noriyoshi Fukushima; Joji Kitayama; Naohiro Sata
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

2.  Impact of Osteopenia on Oncologic Outcomes After Curative Resection for Pancreatic Cancer.

Authors:  Takashi Motomura; Hideaki Uchiyama; Tomohiro Iguchi; Mizuki Ninomiya; Rintaro Yoshida; Takuya Honboh; Noriaki Sadanaga; Tetsuro Akashi; Hiroshi Matsuura
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

3.  Computed tomography-measured bone mineral density as a surrogate marker of survival after resection of colorectal liver metastases.

Authors:  Shinichi Ikuta; Tsukasa Aihara; Takayoshi Nakajima; Meidai Kasai; Naoki Yamanaka
Journal:  Ann Transl Med       Date:  2021-01

Review 4.  Prognostic value of preoperative low bone mineral density in patients with digestive cancers: a systematic review and meta-analysis.

Authors:  Jun Watanabe; Akihiro Saitsu; Atsushi Miki; Kazuhiko Kotani; Naohiro Sata
Journal:  Arch Osteoporos       Date:  2022-02-11       Impact factor: 2.617

5.  Bone Mineral Density as an Individual Prognostic Biomarker in Patients with Surgically-Treated Brain Metastasis from Lung Cancer (NSCLC).

Authors:  Inja Ilic; Anna-Laura Potthoff; Valeri Borger; Muriel Heimann; Daniel Paech; Frank Anton Giordano; Leonard Christopher Schmeel; Alexander Radbruch; Patrick Schuss; Niklas Schäfer; Ulrich Herrlinger; Hartmut Vatter; Asadeh Lakghomi; Matthias Schneider
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.